Inmune Bio earnings were -$18.4M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest INMB earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$1.3M, down 76.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, INMB reported annual earnings of -$45.9M, with 9.2% growth. The next INMB earnings date is Oct 29, 2026.
On INMB's earnings call on Aug 6, 2026, Inmune Bio (NASDAQ: INMB) reported Q2 2026 earnings per share (EPS) of -$0.05, up 95.24% year over year. Total INMB earnings for the quarter were -$1.27 million. In the same quarter last year, Inmune Bio's earnings per share (EPS) was -$1.05.
The next INMB earnings date is Oct 29, 2026. Add INMB to your watchlist to be reminded of Inmune Bio's next earnings date.
Is Inmune Bio profitable or losing money?
As of the last Inmune Bio earnings report, Inmune Bio is currently losing money. Inmune Bio's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$18.42 million, a 66.82% decrease year over year.
What was INMB's earnings growth in the past year?
As of Inmune Bio's earnings date in Aug 6, 2026, Inmune Bio's earnings has grown year over year. INMB earnings in the past year totalled -$18.42 million.
What are Inmune Bio's earnings expectations?
The current EPS estimate for Inmune Bio's earnings report in Oct 29, 2026 is -$0.18.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.